MAY 26, 2017 8:24 AM PDT

Ebola Virus Doesn't Infect Immune Cells, But It Does Kill Them

WRITTEN BY: Kara Marker

How does the Ebola virus prevent immune cells from doing their job - protecting the body from infection - if it doesn’t actually invade them? In a new study from the University of Texas Medical Branch at Galveston and their collaborators, researchers investigate a unique ability of Ebola, with hope that the solution could be translated into clinical practice for new Ebola virus treatments.

Scientists around the world have developed vaccines and treatments for the Ebola virus in response to the (re)emergence of the disease in March of 2014 in Guinea. However, none of these experimental approaches have been approved yet.

"Understanding how the invading Ebola virus shuts down the host's immune systems is a very important step in developing targeted therapies for Ebola virus disease,” said senior author Alexander Bukreyev, PhD.

Bukreyev and his team found that Ebola viruses don’t invade lymphocytes, also known as immune cells; they bind them from the surface of the cell. Before the beginning of the present study, scientists knew that Ebola virus interacts with a lymphocyte signaling pathway after binding TLR4, a lymphocyte receptor. But how does this interaction and binding lead to the destruction of immune cells? What role does TLR4 play?

Instead of infecting lymphocytes, Ebola viruses bind the cells and induce cell death. TLR4 acts as an unfortunate middleman, facilitating the signals needed to initiate cell death. An Ebola infection leads to death in part because the virus eliminates a majority of the host’s infection-fighting immune cells. People who survive Ebola infections tend to have persistent populations of immune cells that somehow managed to avoid distinction by the Ebola virus.

A new anti-Ebola virus solution based on this finding: blocking TLR4 activation to prevent Ebola-conducted immune cell death. "Our findings suggest that a drug that blocks TLR4 could be used to treat patients with Ebola and extend our earlier findings that the TLR4 receptor antagonist Eritoran protects against both Ebola and the closely related Marburg virus," explained co-lead author Patrick Younan, PhD.

More about Ebola:

An infection with the Ebola virus causes a hemorrhagic fever with a fatality rate of above 50 percent. While no drug therapies have been officially approved yet, symptomatic treatment and rehydration are two approaches useful to increasing survival rates.

The present study was published in the journal PLOS Pathogens.

Sources: Centers for Disease Control and Prevention, World Health Organization, University of Texas Medical Branch at Galveston

About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
AUG 18, 2021
Neuroscience
Histamine Regulates Serotonin Levels in Depression
AUG 18, 2021
Histamine Regulates Serotonin Levels in Depression
Heightened histamine levels from inflammation inhibit the effects of the mood-regulating neurotransmitter serotonin in t ...
AUG 23, 2021
Cancer
A Safe and Effective Combination Therapy for Advanced Cancer
AUG 23, 2021
A Safe and Effective Combination Therapy for Advanced Cancer
Immunotherapies are emerging as a promising strategy for the treatment of late-stage cancers which currently have m ...
OCT 12, 2021
Immunology
Major Landmark in a 100-Year Search for a Malaria Vaccine
OCT 12, 2021
Major Landmark in a 100-Year Search for a Malaria Vaccine
In one of the greatest global health milestones of our time, the World Health Organization has approved the widespread d ...
OCT 19, 2021
Immunology
Mild COVID Produces Better Than Expected Antibody Responses
OCT 19, 2021
Mild COVID Produces Better Than Expected Antibody Responses
Over millions of years, the immune system has evolved to shield us against disease-causing pathogens that we encounter e ...
OCT 18, 2021
Genetics & Genomics
A Decade After Gene Therapy, SCID Patients Are Doing Well
OCT 18, 2021
A Decade After Gene Therapy, SCID Patients Are Doing Well
For decades, scientists have been trying to find ways to cure disorders that can be traced back to an error in one gene. ...
NOV 30, 2021
Immunology
The Body Makes Its Own Anti-inflammatory 'Cannabis' After a Workout
NOV 30, 2021
The Body Makes Its Own Anti-inflammatory 'Cannabis' After a Workout
Feeling great after hitting the gym? That’s because of the flood of endorphins released into the body after a bout ...
Loading Comments...